NetworkNewsBreaks – VBI Vaccines, Inc. (NASDAQ: VBIV) Trades Higher on Positive Scientific Advice from EMA
VBI Vaccines (NASDAQ: VBIV) ("VBI") this morning said it has received positive scientific advice regarding its European development path for its Sci-B-Vac™ vaccine from the European Medical Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). In its letter, the CHMP stated its support of VBI's proposed plan to proceed to the phase III clinical studies of Sci-B-Vac™, and agreed that the product information and data from ongoing studies supports the phase III clinical studies and VBI's planned filing of a market authorization application. The company is also evaluating plans for the pivotal phase III clinical studies with the…